NGM Biopharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:NGM Biopharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014051
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
NGM Biopharmaceuticals Inc (NGM Bio) is a clinical stage biopharmaceutical company which focuses on the development of drug discovery platform to generate biologic drug candidates to treat cardio-metabolic, immuno-oncology and liver diseases. Its product pipeline includes NGM282, NGM386, NGM395, NGM313, NGM217 and NGM120. The company’s drug candidates are being developed for the treatment of various therapeutic indications such as obesity, diabetes, oncology and other indications. NGM Bio developed a biologics platform that incorporates multiple technologies to generate and screen monoclonal antibodies. The company works in collaboration with Merck to discover, develop and commercialize new biologic drugs. NGM Bio is headquartered in South San Francisco, California, the US.

NGM Biopharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
NGM Biopharma Raises USD106 Million in Series E Financing 11
NGM Biopharmaceuticals Secures $36.8 Million Series D Financing 12
NGM Biopharma Raises USD20.7 Million in Series D Financing 13
NGM Biopharma Raises US$50 Million In Series C Venture Financing 14
NGM BioPharma Raises US$16.9 Million In Fourth Tranche Of Series B Financing 15
Partnerships 16
NGM Biopharma Enters into R&D Agreement with Merck for Novel Biologic Therapeutics 16
MedImmune Enters Into Co-Development Agreement With NGM Biopharma 17
Daiichi Sankyo Enters Into Co-Development Agreement With NGM Biopharma For Diabetes Drugs 18
Licensing Agreements 19
NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 19
Equity Offering 20
NGM Biopharma Plans IPO 20
NGM Biopharmaceuticals Inc – Key Competitors 21
NGM Biopharmaceuticals Inc – Key Employees 22
NGM Biopharmaceuticals Inc – Locations And Subsidiaries 23
Head Office 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
NGM Biopharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
NGM Biopharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
NGM Biopharma Raises USD106 Million in Series E Financing 11
NGM Biopharmaceuticals Secures $36.8 Million Series D Financing 12
NGM Biopharma Raises USD20.7 Million in Series D Financing 13
NGM Biopharma Raises US$50 Million In Series C Venture Financing 14
NGM BioPharma Raises US$16.9 Million In Fourth Tranche Of Series B Financing 15
NGM Biopharma Enters into R&D Agreement with Merck for Novel Biologic Therapeutics 16
MedImmune Enters Into Co-Development Agreement With NGM Biopharma 17
Daiichi Sankyo Enters Into Co-Development Agreement With NGM Biopharma For Diabetes Drugs 18
NGM Biopharma Enters Into Licensing Agreement With Janssen Pharma For New Diabetes Drugs 19
NGM Biopharma Plans IPO 20
NGM Biopharmaceuticals Inc, Key Competitors 21
NGM Biopharmaceuticals Inc, Key Employees 22

★海外企業調査レポート[NGM Biopharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Saertex GmbH & Co KG:企業の戦略的SWOT分析
    Saertex GmbH & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Purdue Pharma LP:企業の戦略的SWOT分析
    Purdue Pharma LP - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • Gordon Food Service, Inc.:企業の戦略・SWOT・財務情報
    Gordon Food Service, Inc. - Strategy, SWOT and Corporate Finance Report Summary Gordon Food Service, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Petroleo Brasileiro SA Oil & Gas Exploration and Production Operations and Cost Analysis – Q3, 2017
    Petroleo Brasileiro SA Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2017 Summary Petroleo Brasileiro SA Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive info …
  • Rabigh Refining & Petrochemical Co (2380):企業の財務・戦略的SWOT分析
    Rabigh Refining & Petrochemical Co (2380) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Ethiopian Electric Power Corp:電力:M&Aディール及び事業提携情報
    Summary Ethiopian Electric Power Corp (Ethiopian Electric Power), formerly The Ethiopian Electric Light and Power Authority, is an electric utility that generates, transmits and distributes electricity. The utility maintains the Interconnected System and transmits electricity from hydropower plants …
  • Bank of Queensland Limited (BOQ):企業の財務・戦略的SWOT分析
    Bank of Queensland Limited (BOQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Meiji Seika Pharma Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Meiji Seika Pharma Co Ltd (Meiji Seika Pharma), a subsidiary of Meiji Holdings Co Ltd, is a pharmaceutical solutions provider that carries out manufacturing and sale of ethical pharmaceuticals, agricultural chemicals and veterinary drugs. The company provides Streptomycin Meiji, Kanamycin Me …
  • Natera Inc (NTRA):企業の製品パイプライン分析
    Summary Natera Inc (Natera), formerly Gene Security Network Inc is a genetic testing and diagnostics company that develops and commercializes non-invasive methods for DNA analysis. The company offers Panorama, a non-invasive prenatal screening test that analyzes baby's DNA through a simple blood dra …
  • Merlin Diamonds Limited:企業の戦略・SWOT・財務情報
    Merlin Diamonds Limited - Strategy, SWOT and Corporate Finance Report Summary Merlin Diamonds Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • AiCuris GmbH & Co KG:製薬・医療:M&Aディール及び事業提携情報
    Summary AiCuris GmbH & Co KG (AiCuris) a subsidiary of Santo Holding AG is a drug development company that discovers and develops antibacterial and antiviral agents for the treatment of life-threatening infectious diseases. The company’s pipeline products include antiviral and antibacterial agents f …
  • Korea South-East Power Co Ltd:企業の戦略的SWOT分析
    Korea South-East Power Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Meridian Bancorp Inc (EBSB):企業の財務・戦略的SWOT分析
    Meridian Bancorp Inc (EBSB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • QDVC Q.S.C:企業の戦略的SWOT分析
    QDVC Q.S.C - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Tommy Hilfiger Group:企業の戦略・SWOT・財務情報
    Tommy Hilfiger Group - Strategy, SWOT and Corporate Finance Report Summary Tommy Hilfiger Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Tenaska Inc:電力:M&Aディール及び事業提携情報
    Summary Tenaska Inc (Tenaska) is an independent power development and energy marketing company. It develops, designs, finances, and manages and operates power plants. The company purchases and sells natural gas, electric capacity, energy, and renewable energy products; acquires, manages, and optimiz …
  • Foundation Radiology Group PC-医療機器分野:企業M&A・提携分析
    Summary Foundation Radiology Group PC (FRG) is a radiology solutions provider. The company provides radiological services in areas of pediatric, neurology, mammography, musculoskeletal, PET and CT, cardiac CT and interventional radiology. It provides imaging solutions for the radiologists and system …
  • ThromboGenics NV (THR)-製薬・医療分野:企業M&A・提携分析
    Summary ThromboGenics NV (ThromboGenics) is a biotechnology company, which develops and commercializes ophthalmic and cancer medicines. The company’s ocriplasmin, a recombinant derivative of the plasmin protein, is commercialized as Jetrea in the US to treat symptomatic vitreomacular adhesion (VMA) …
  • NOV Inc (NOV):企業の財務・戦略的SWOT分析
    NOV Inc (NOV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Novacyt SA (ALNOV):企業の製品パイプライン分析2018
    Summary Novacyt SA (Novacyt) is a medical device company that develops and markets medical cytology solutions. The company offers oncology and infectious disease diagnostic products. It also sells diagnostic reagents used in LBC, oncology, microbiology, haematology and serology testing. Novacyt deve …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆